Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Indirect Ophthalmoscopy Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4170g - Indirect Ophthalmoscopy Screening

- 21/3/18 - 1 Formulaire, 4 Groupes Item, 48 Eléments de données, 1 Langue

Groupes Item: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye

Study part: Indirect Ophthalmoscopy Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Indirect Ophthalmoscopy Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4168g - Indirect Ophthalmoscopy Screening

- 21/3/18 - 1 Formulaire, 4 Groupes Item, 48 Eléments de données, 1 Langue

Groupes Item: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye

Study part: Indirect Ophthalmoscopy Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

INDIRECT OPHTHALMOSCOPY (DAY 7) CRFs Roche FVF4170G Macular Edema NCT00473382

- 11/6/17 - 1 Formulaire, 3 Groupes Item, 22 Eléments de données, 1 Langue

Groupes Item: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 7), INDIRECT OPHTHALMOSCOPY (DAY 7)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (DAY 7) CRFs Roche FVF4168G Macular Edema NCT00473330

- 11/6/17 - 1 Formulaire, 3 Groupes Item, 22 Eléments de données, 1 Langue

Groupes Item: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 7), INDIRECT OPHTHALMOSCOPY (DAY 7)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (DAY 0) CRFs Roche FVF4170G Macular Edema NCT00473382

- 9/6/17 - 1 Formulaire, 3 Groupes Item, 21 Eléments de données, 1 Langue

Groupes Item: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 0), INDIRECT OPHTHALMOSCOPY (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 8/6/17 - 1 Formulaire, 3 Groupes Item, 45 Eléments de données, 1 Langue

Groupes Item: Patient administration, INDIRECT OPHTHALMOSCOPY (SCREENING), INDIRECT OPHTHALMOSCOPY (SCREENING)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 8/6/17 - 1 Formulaire, 3 Groupes Item, 21 Eléments de données, 1 Langue

Groupes Item: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 0), INDIRECT OPHTHALMOSCOPY (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (SCREENING) CRFs Roche FVF4168G Macular Edema NCT00473330

- 8/6/17 - 1 Formulaire, 3 Groupes Item, 45 Eléments de données, 1 Langue

Groupes Item: Patient administration, INDIRECT OPHTHALMOSCOPY (SCREENING), INDIRECT OPHTHALMOSCOPY (SCREENING)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

GSK Eltrombopag Thrombocytopenia, Clinical Study ID: 105122 - Slit lamp, Biomicrosopy, Visual acuity and indirect ophthalmoscopy

- 12/12/20 - 1 Formulaire, 5 Groupes Item, 26 Eléments de données, 1 Langue

Groupes Item: Administrative Data, slit lamp examination, slit lamp biomicroscopy, visual acuity, Indirect Ophtalmoscopy

The primary objective of this study was to demonstrate bioequivalence between eltrombopag oral film-coated tablets manufactured at Research and Development (R&D) and Commercial sites. The subject participants each went through two dosing periods (Period 1 and Period 2), during each of which they received a single dose of eltrombopag. The dosing periods were separated by a washout of at least 10 days. For each period, subjects had to perform a visit on the day before and one on the day of the administration of the drug. Furthermore, the protocol-defined visits included a screening visit and a follow-up visit. Study ID: 105122 Clinical Study ID: 105122 Study Title: Phase I Bioequivalence Study for SB 497115 GR Phase II and Phase III Tablets Sponsor: GlaxoSmithKline Phase: phase 1 Study Recruitment Status: Completed Generic Name: Eltrombopag Study Indication: Thrombocytopenia This form has to be filled out at the Screening and Follow-Up Visits.

Mots-clés

Table des matières

Modèles de données sélectionnés